New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - goserelin acetate 12.5mg equivalent to 10.8 mg goserelin - subcutaneous implant - 10.8 mg - active: goserelin acetate 12.5mg equivalent to 10.8 mg goserelin excipient: poly(lactide) polyglactin - prostate cancer suitable for hormonal manipulation. adjuvant and neoadjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - goserelin acetate 4.1mg equivalent to 3.6 mg goserelin - subcutaneous implant - 3.6 mg - active: goserelin acetate 4.1mg equivalent to 3.6 mg goserelin excipient: polyglactin - prostate cancer suitable for hormonal manipulation. adjuvant and neoadjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation

Israel - English - Ministry of Health

astrazeneca (israel) ltd - goserelin as acetate - implant for injection - goserelin as acetate 10.8 mg/unit - goserelin - goserelin - prostate cancer suitable for hormonal manipulation.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - goserelin as acetate - implant - goserelin as acetate 3.6 mg/unit - goserelin - goserelin - treatment of prostate cancer suitable for hormonal manipulation. breast cancer in pre-menopausal women suitable for hormone manipulation.endometriosis. assisted reproduction: pituitary down regulation in preparion for superovulation. endometrial thinning: zoladex is indicated for the prethinning of the utetine endometrium prior ro endometrial ablation or resection. uterine fibroids: for reduction of fibroid size prior to surgery.

Malta - English - Medicines Authority

boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - goserelin acetate - implant - goserelin acetate 10.8 milligram(s) - endocrine therapy

Malta - English - Medicines Authority

boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - goserelin acetate - implant - goserelin acetate 3.6 milligram(s) - endocrine therapy

Malta - English - Medicines Authority

uab boston biopharma lt v.a. graiciuno g. 6-2 vilniaus m. sav. lt-02241, lithuania - goserelin acetate - implant - goserelin acetate 3.6 mg - endocrine therapy

Malta - English - Medicines Authority

uab boston biopharma lt v.a. graiciuno g. 6-2 vilniaus m. sav. lt-02241, lithuania - goserelin acetate - implant - goserelin acetate 10.8 mg - endocrine therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 10.8 mg - implant - excipient ingredients: polyglactin - for the treatment of advanced prostate cancer. bicalutamide is also indicated for the prevention of disease flare associated with initial goserelin treatment

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - for the treatment of advanced prostate cancer. bicalutamide is also indicated for the prevention of disease flare associated with initial goserelin treatment.